Press release
Hyperhidrosis Therapeutics Pipeline Analysis - Dermira, Inc., Allergan, TheraVida, Inc., Brickell Biotech, Inc.
Allergan Plc, TheraVida Inc., and GlaxoSmithKline Plc have one drug candidate each in the Phase II development for the treatment of hyperhidrosis. Glycopyrronium tosylate is the only drug candidate that has the Phase III stage of development for the treatment of hyperhidrosis. Majority of the pipeline drug candidates are being developed using the topical route of administration.
Download report sample at: https://www.psmarketresearch.com/market-analysis/hyperhidrosis-therapeutics-pipeline-analysis/report-sample
Major players in the market are putting more emphasis on targeting cholinergic receptors. The drug candidates used for the treatment of hyperhidrosis, act on cholinergic receptors and block its activity that interfere with sweating. For instance, Glycopyrronium tosylate, a Phase III drug candidate by Dermira, Inc. acts topically and blocks the cholinergic receptor.
Some of the key players developing drugs for the treatment of hyperhidrosis include Dermira, Inc., Allergan plc, TheraVida Inc. and others.
Browse report at: https://www.psmarketresearch.com/market-analysis/hyperhidrosis-therapeutics-pipeline-analysis
Hyperhidrosis Therapeutics Pipeline Analysis
• By Phase
• By Molecule Type
• By Route of Administration
• By Company
About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
347 5th Ave. #1402- 210
New York City, NY 10016 United States
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hyperhidrosis Therapeutics Pipeline Analysis - Dermira, Inc., Allergan, TheraVida, Inc., Brickell Biotech, Inc. here
News-ID: 1386845 • Views: …
More Releases from P&S Intelligence
U.S. ESG Investments Market Set to Skyrocket: $16 Trillion by 2032
According to the latest market research study published by P&S Intelligence, the U.S. Environmental, Social, and Governance (ESG) investments market is experiencing a significant surge, with projections indicating an increase from $6.5 trillion in 2024 to an estimated $16.0 trillion by 2032. This represents a robust compound annual growth rate (CAGR) of 12.1% over the forecast period.
According to a comprehensive analysis by P&S Intelligence, the market's expansion is driven…
Facility Management in the U.K. Booms with 14.1% CAGR as Demand Soars Across Sec …
According to the latest market research study published by P&S Intelligence, the U.K. facility management market is poised for significant growth, with projected revenues reaching USD 2,743.3 million in 2024 and expected to soar to USD 6,038.4 million by 2030, reflecting a robust CAGR of 14.1% during the forecast period.
This expansion is fueled by a surge in demand across both public and private sectors. According to the RICS U.K.…
Point-of-Sale Software Market in the U.S. Set to Grow by 9.7% CAGR, Boosted by O …
According to the latest market research study published by P&S Intelligence, the U.S. point-of-sale (POS) software market, valued at USD 4.7 billion in 2024, is poised for significant growth over the coming years, with projections estimating it will reach USD 9.8 billion by 2032, expanding at a compound annual growth rate (CAGR) of 9.7%. This growth is attributed to rapid technological advancements, a surge in mobile and cloud-based POS systems,…
Competitive Landscape of the Industrial Starches Market: Key Players, Trends, an …
According to the latest market research study published by P&S Intelligence, the global industrial starches market is poised for significant growth, with a projected increase from USD 110.3 billion in 2024 to USD 169.9 billion by 2030, at a robust compound annual growth rate (CAGR) of 7.5%. Industrial starches play a crucial role in diverse sectors, including food, pharmaceuticals, and paper, driven by their unique properties such as stabilizing, thickening,…
More Releases for Dermira
Topical Use Acne Treatment Market Growth, Segments, And Forecast to 2033 Roche, …
Topical acne treatments work by targeting the underlying causes of acne, such as excess oil production, clogged pores, and bacteria. A variety of active ingredients can be used in these treatments, including benzoyl peroxide, which helps to kill acne-causing bacteria; salicylic acid, which exfoliates the skin and unblocks pores; and retinoids, which promote cell turnover and prevent clogged follicles. In recent years, natural remedies such as tea tree oil and…
Axillary Hyperhidrosis Drug Market Growth Holds Strong | Allergan, Brickell Biot …
Latest Study on Industrial Growth of Worldwide Axillary Hyperhidrosis Drug Market 2024-2030. A detailed study accumulated to offer the Latest insights about acute features of the Worldwide Axillary Hyperhidrosis Drug market. The report contains different market predictions related to revenue size, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of…
Latest Research and Development in the Axillary Hyperhidrosis Market | Key Compa …
The Axillary Hyperhidrosis market report provides current treatment practices, emerging drugs, Axillary Hyperhidrosis market share of the individual therapies, current and forecasted Axillary Hyperhidrosis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Axillary Hyperhidrosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Axillary Hyperhidrosis market.
Recent Developmental…
Palmar Hyperhidrosis Market Comprehensive Analysis on types and application 2020 …
Global Palmar Hyperhidrosis Market Size, Status and Forecast 2020
"Palmar Hyperhidrosis - Pipeline Insight, 2020," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Palmar Hyperhidrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Our new sample…
Topical Use Acne Treatment Market 2020 Dazzling Industry Growth | Dermira, GUTHY …
Global Topical Use Acne Treatment Market is expected to rise from its initial estimated value of USD 5.33 billion in 2018 to an estimated value of USD 7.47 billion by 2026, registering a CAGR of 4.3% in the forecast period of 2019-2026. This rise in market value can be attributed to the rising disposable income.
Get Sample Report @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-topical-use-acne-treatment-market
Key Market Competitors: Global Topical Use Acne Treatment Market
Few of the major…
Hyperhidrosis Therapeutics - Pipeline Analysis with Key Players Dermira, Inc., A …
The study analyzed that the hyperhidrosis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development.
Download report sample at: https://www.psmarketresearch.com/market-analysis/hyperhidrosis-therapeutics-pipeline-analysis/report-sample
*Insights on pipeline segments
Allergan Plc, TheraVida Inc., and GlaxoSmithKline Plc have one drug candidate each in the Phase II development for the treatment of hyperhidrosis. Glycopyrronium tosylate is the only drug candidate that has the Phase III stage of development for the treatment of hyperhidrosis. Majority of the pipeline…
